Trastuzumab Recruiting Phase 2 Trials for Progesterone Receptor Negative / Triple-Negative Breast Cancer (TNBC) / Progesterone Receptor-negative Breast Cancer / Estrogen Receptor Positive / Stage IIA Breast Cancer / Triple-Negative Breast Carcinoma / Her2-Positive Breast Cancer / Progesterone Receptor Positive / HER2/Neu Positive / Estrogen Receptor-negative Breast Cancer / Stage IA Breast Cancer / Stage II Breast Cancer / Stage III Breast Cancer / HER2/Neu Negative / Progesterone Receptor-positive Breast Cancer / Invasive Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIA Breast Cancer / Estrogen Receptor Negative / Stage IIB Breast Cancer / Stage IIIC Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer Treatment

RecruitingTreatment2 IdentifierTitleDrugs
NCT01750073Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer
NCT03238495Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
NCT03933319Phase Ⅱ Study of Pegylated Liposomal Doxorubicin(PLD)Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
NCT03125928Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT03094052Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy
NCT03140553TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer